EP1239051A3 — Human posh-like protein 1
Assigned to Aeomica Inc · Expires 2004-03-17 · 22y expired
What this patent protects
The invention provides isolated nucleic acids that encode human POSHL1, and fragments thereof, vectors for propagating and expressing human POSHL1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein…
USPTO Abstract
The invention provides isolated nucleic acids that encode human POSHL1, and fragments thereof, vectors for propagating and expressing human POSHL1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel human POSHL1 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human POSHL1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human POSHL1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human POSHL1 nucleic acids, proteins, and antibodies of the present invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.